MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,818.93
+0.58%
NASDAQ 100
$31,224.47
+0.48%
DOW JONES
$51,521.00
+0.49%
NASDAQ Composite
$27,599.79
+0.45%
RUSSELL 2000
$2,813.40
-0.72%
CBOE VIX
$15.01
-3.29%
Sector Heatmap
Technology+0.53%
Financials+0.24%
Healthcare-0.17%
Consumer Cycl+1.20%
Consumer Staples+0.90%
Energy+0.47%
Industrials+0.87%
Materials+0.46%
Real Estate+1.06%
Utilities+2.98%
Comm Services+0.04%
NGEN — NervGen Pharma Corp. Common stock
NasdaqNervGen Pharma Corp. Common stock
$1.75
-0.06(-3.31%)
- O
- 1.81
- H
- 1.82
- L
- 1.73
- V
- 297.25K
⏱️ End-of-day dataAs of Oct 6, 2026
Chart
About NGEN
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
IndustryCommon Stock
SectorNot available
IPO DateMar 25, 2019
Employees9
Stock ExchangeNasdaq
Ticker SymbolNGEN
Websitehttps://www.nervgen.com
Key Financial Statistics
| Market Cap | $191.39M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $1.58 - $6.30 |
| 52-Week Avg Volume | 418.5K |
| VWAP | $1.78 |
| Transactions | 1,817 |
| Total Recorded Bars | 1,888 days |